Author: Oddy, Christopher; McCaul, James; Keeling, Polly; Allington, Jonathan; Senn, Dhanuja; Soni, Neesha; Morrison, Hannah; Mawella, Ruwani; Samuel, Thomas; Dixon, John
Title: Pharmacological Predictors of Morbidity and Mortality in COVIDâ€19 Cord-id: ahq57bld Document date: 2021_4_28
ID: ahq57bld
Snippet: The interaction of COVIDâ€19 with the majority of common prescriptions is broadly unknown. The purpose of this study is to identify medications associated with altered disease outcomes in COVIDâ€19. A retrospective cohort comprised of all adult inpatient admissions to our centre with COVIDâ€19 was analysed. Data concerning all antecedent prescriptions were collected and agents brought forward for analysis if prescribed to at least 20 patients in our cohort. Fortyâ€two medications and 22 clas
Document: The interaction of COVIDâ€19 with the majority of common prescriptions is broadly unknown. The purpose of this study is to identify medications associated with altered disease outcomes in COVIDâ€19. A retrospective cohort comprised of all adult inpatient admissions to our centre with COVIDâ€19 was analysed. Data concerning all antecedent prescriptions were collected and agents brought forward for analysis if prescribed to at least 20 patients in our cohort. Fortyâ€two medications and 22 classes of medication were examined. Groups were propensity score matched and analysed by logistic and linear regression. The majority of medications did not show a statistically significant relationship with altered disease outcomes. Lower mortality was associated with use of pregabalin (p = 0.049, HR = 0.10 [0.01â€0.92]), inhalers of any type (p = 0.015, HR = 0.33 [0.14â€0.80]) and specifically beclomethasone (p = 0.032, HR = 0.10 [0.01â€0.82]), tiotropium (p = 0.035, HR = 0.07 [0.01â€0.83]) and steroid containing inhalers (p = 0.013, HR = 0.35 [0.15â€0.79]). Gliclazide (p = 0.020, HR = 4.37 [1.26â€15.18]) and proton pump inhibitor (p = 0.028, HR = 1.72 [1.06â€2.79]) use was associated with greater mortality. Diuretic (p = 0.002, HR = 0.07 [0.01â€0.37]) and statin (p = 0.006, HR = 0.35 [0.17â€0.73]) use was associated with lower rates of critical care admission. Our data lends confidence to observing usual practice in COVIDâ€19 patients by continuing antecedent prescriptions in the absence of an alternative acute contraindication. We highlight potential benefits in investigation of diuretics, inhalers, pregabalin and statins as therapeutic agents for COVIDâ€19 and support further assessment of the safety of gliclazide and PPIs in the acute illness. This article is protected by copyright. All rights reserved
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date